ZA200209087B - Use of lactobacillus casei in immunostimulatory peptides. - Google Patents

Use of lactobacillus casei in immunostimulatory peptides.

Info

Publication number
ZA200209087B
ZA200209087B ZA200209087A ZA200209087A ZA200209087B ZA 200209087 B ZA200209087 B ZA 200209087B ZA 200209087 A ZA200209087 A ZA 200209087A ZA 200209087 A ZA200209087 A ZA 200209087A ZA 200209087 B ZA200209087 B ZA 200209087B
Authority
ZA
South Africa
Prior art keywords
lactobacillus casei
immunostimulatory peptides
immunostimulatory
peptides
casei
Prior art date
Application number
ZA200209087A
Other languages
English (en)
Inventor
Eric Postaire
Benjamin Bonavida
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200209087(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of ZA200209087B publication Critical patent/ZA200209087B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200209087A 2000-05-25 2002-11-08 Use of lactobacillus casei in immunostimulatory peptides. ZA200209087B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0006679A FR2809312B1 (fr) 2000-05-25 2000-05-25 Utilisation de l. casei dans des compositions immunostimulantes

Publications (1)

Publication Number Publication Date
ZA200209087B true ZA200209087B (en) 2004-06-30

Family

ID=8850597

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200209087A ZA200209087B (en) 2000-05-25 2002-11-08 Use of lactobacillus casei in immunostimulatory peptides.

Country Status (28)

Country Link
US (1) US7604809B2 (hu)
EP (1) EP1283714B1 (hu)
JP (1) JP2003534284A (hu)
CN (1) CN1194707C (hu)
AR (1) AR028626A1 (hu)
AT (1) ATE332143T1 (hu)
AU (2) AU5643501A (hu)
BG (1) BG65884B1 (hu)
BR (1) BR0111135A (hu)
CA (1) CA2410350C (hu)
CZ (1) CZ303600B6 (hu)
DE (1) DE60121327T2 (hu)
DK (1) DK1283714T3 (hu)
EA (1) EA005081B1 (hu)
ES (1) ES2267763T3 (hu)
FR (1) FR2809312B1 (hu)
HK (1) HK1055898A1 (hu)
HR (1) HRP20020935A2 (hu)
HU (1) HUP0302041A3 (hu)
IL (1) IL152980A0 (hu)
MA (1) MA25760A1 (hu)
MX (1) MXPA02011636A (hu)
NO (1) NO332369B1 (hu)
PL (1) PL201801B1 (hu)
PT (1) PT1283714E (hu)
SK (1) SK18272002A3 (hu)
WO (1) WO2001089541A1 (hu)
ZA (1) ZA200209087B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
GB0009294D0 (en) 2000-04-15 2000-05-31 Sec Dep For The Home Departmen Improvements in and relating to analysis of DNA samples
US9610347B2 (en) * 2001-04-30 2017-04-04 Cortcontrol Vaccination response for immunodeficiency or high cortisol
CN1317385C (zh) * 2003-05-30 2007-05-23 上海光明乳业股份有限公司 干酪乳杆菌Bd－II菌株及其在降低血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
PT1629850E (pt) * 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
WO2006064449A1 (en) * 2004-12-15 2006-06-22 Van Der Westhuizen Cornelis Fl Detoxifying and immunity-booster composition
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
ES2264368B1 (es) * 2005-02-11 2007-12-01 Francisco Exposito Mesa Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos.
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
WO2006130187A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic lactobacilli
AU2007294122B2 (en) 2006-09-10 2013-03-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
FR2912657B1 (fr) * 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
WO2009067000A1 (en) * 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
EP2291086A1 (en) * 2008-05-13 2011-03-09 Glycotope GmbH Fermentation process
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2153837A1 (en) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
FR2937252B1 (fr) * 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
BR112012016894A2 (pt) * 2010-01-08 2015-09-15 Gervais Danone Sa lactobacilos com ação antioxidante.
EP2545160B1 (en) * 2010-03-12 2018-07-18 Compagnie Gervais Danone Lactic acid bacteria for coeliac disease
US20130195917A1 (en) * 2010-10-15 2013-08-01 Dorte Eskesen Immunoadjuvant
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
CA2844543A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
SG11202010493XA (en) 2018-05-18 2020-11-27 Glycotope Gmbh Anti-muc1 antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236872A (ja) * 1992-02-27 1993-09-17 Takanashi Nyugyo Kk 乳酸菌含有食品
JP4112021B2 (ja) * 1994-02-16 2008-07-02 明治乳業株式会社 乳酸菌を用いた免疫賦活剤
ATE173135T1 (de) * 1995-01-02 1998-11-15 Gervais Danone Co Milchsäureferment, und ihre verwendung zur herstellung von antidiarrhöeprodrukten
US6379663B1 (en) * 1997-08-21 2002-04-30 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
US6699517B2 (en) * 1997-11-28 2004-03-02 Compagnie Gervais Danone Method for preparing food products by fermenting soy milk with streptococcus thermophilus
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
KR100324441B1 (ko) * 1999-02-08 2002-02-27 이은선 위염, 위궤양, 십이지장궤양 예방을 위한 식품

Also Published As

Publication number Publication date
CA2410350A1 (fr) 2001-11-29
JP2003534284A (ja) 2003-11-18
MXPA02011636A (es) 2003-05-14
DE60121327T2 (de) 2007-07-26
AU2001256435B2 (en) 2006-06-29
AR028626A1 (es) 2003-05-14
BR0111135A (pt) 2003-04-08
EP1283714B1 (fr) 2006-07-05
HUP0302041A3 (en) 2005-11-28
PL358408A1 (en) 2004-08-09
US7604809B2 (en) 2009-10-20
HUP0302041A2 (hu) 2003-09-29
HRP20020935A2 (en) 2005-02-28
BG107299A (bg) 2003-07-31
CA2410350C (fr) 2013-04-09
EP1283714A1 (fr) 2003-02-19
FR2809312A1 (fr) 2001-11-30
CN1430518A (zh) 2003-07-16
PT1283714E (pt) 2006-11-30
HK1055898A1 (en) 2004-01-30
ES2267763T3 (es) 2007-03-16
IL152980A0 (en) 2003-06-24
MA25760A1 (fr) 2003-04-01
EA005081B1 (ru) 2004-10-28
PL201801B1 (pl) 2009-05-29
DE60121327D1 (de) 2006-08-17
EA200201248A1 (ru) 2003-06-26
FR2809312B1 (fr) 2002-07-12
ATE332143T1 (de) 2006-07-15
SK18272002A3 (sk) 2003-08-05
NO20025595D0 (no) 2002-11-21
BG65884B1 (bg) 2010-04-30
NO20025595L (no) 2003-01-22
CZ20024189A3 (cs) 2003-05-14
CN1194707C (zh) 2005-03-30
US20040029127A1 (en) 2004-02-12
CZ303600B6 (cs) 2013-01-02
NO332369B1 (no) 2012-09-03
DK1283714T3 (da) 2006-10-30
WO2001089541A1 (fr) 2001-11-29
AU5643501A (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ZA200209087B (en) Use of lactobacillus casei in immunostimulatory peptides.
AU2001256435A1 (en) Use of lactobacillus casei in immunostimulatory compositions
IL160050A0 (en) Probiotic lactobacillus casei strains
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
AU7616001A (en) Probiotic recolonisation therapy
AU6079201A (en) Lactobacillus reuteri glucosyltransferase
HUP0600031A2 (en) Kahalalide formulations and their use
AU2001254856A1 (en) Lactococcus lactis genome, polypeptides and uses
EP1343819A4 (en) HLA-A2.1 BINDING SPEPTIDES AND THEIR USE
EP1337543A4 (en) STREPTAVIDINE-BINDING PEPTIDES AND USES THEREOF
SG97174A1 (en) Lactobacillus rhamnosus strain and uses thereof
EP1275659A4 (en) PHYSIOLOGICALLY ACTIVE PEPTIDES AND THEIR USE
HUP0300489A3 (en) Novel protein and gene encoding the same
IL145527A0 (en) Retro-inverso prosaposin-derived peptides and use thereof
GB0018148D0 (en) Peptides and their use
GB0026135D0 (en) Peptides and their use
GB0017028D0 (en) Peptides and their therapeutic use
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
AU2001270451A1 (en) Memory-enhancing peptides and the use thereof
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
AU5995701A (en) Synthetic peptides and uses therefore
GB0003727D0 (en) Virulence gene and protein and their use
GB0002554D0 (en) Virulence gene and protein and their use
GB0002556D0 (en) Virulence gene and protein and their use
GB0002563D0 (en) Virulence gene and protein and their use